Subtype
Pancreatobiliary Carcinoma
CI-CAN-00001365Explore in graph →
700 active trials8 approved drugs60 evidence items
- NCIt
- C166418
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001365Explore in graph →
Clinical trials
2,132 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (303)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05625529 | ExoLuminate Study for Early Detection of Pancreatic Cancer | recruiting | — | 1,000 | Biological DynamicsINDUSTRY | 1 | Jul 28, 2025 | clinicaltrials |
| NCT03806309 | OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC(TEDOPAM) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 25, 2025 |
| clinicaltrials |
| NCT03704480 | Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.(IMMUNO-BIL) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06493734 | Stereotactic Body Radiation Therapy After Chemotherapy for Unresectable Perihilar Cholangiocarcinoma(STRONG II) | recruiting | N/A | 30 | Erasmus Medical CenterOTHER | 2 | Jul 15, 2025 | clinicaltrials |
| NCT07066995 | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer(BAH2573-102) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Jul 15, 2025 | clinicaltrials |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer Patients(TAB-2) | recruiting | Phase 3 | 220 | Tata Memorial CentreOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07062328 | A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC(HP-BTC-002) | not yet recruiting | Phase 2 | 39 | Sun Yat-sen UniversityOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07064447 | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator | not yet recruiting | — | 260 | Germans Trias i Pujol HospitalOTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT06287749 | French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) | recruiting | — | 37 | University Hospital, MontpellierOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT05607953 | Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma | active not recruiting | Phase 1 | 60 | TriSalus Life Sciences, Inc.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06964425 | Raman Spectroscopy in the Diagnosis of Extrahepatic Cholangiocarcinoma - a Pilot Study | recruiting | N/A | 20 | University Hospital OlomoucOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07045571 | MSCAN: ctDNA Methylation as Prognostic and Theranostic Tool for Pancreatic Cancer | recruiting | — | 1,000 | Yingbin Liu, MD, PhD, FACSOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06780553 | Validation of the Proteomic Profiling as a Diagnostic Test for Extra-hepatic Cholangiocarcinoma(PROFI-CHOL) | not yet recruiting | — | 60 | University Hospital, BordeauxOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05451043 | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) | recruiting | Phase 2 | 62 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06643208 | D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC | recruiting | — | 37 | Fujian Provincial HospitalOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06168292 | Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma | recruiting | N/A | 53 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06135896 | Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers(Dulastin) | recruiting | Phase 2 | 98 | National Cancer Center, KoreaOTHER_GOV | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07025174 | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer(SAIB) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07007832 | Bile Omics for Diagnosing Indeterminate Biliary Strictures | recruiting | — | 260 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014254 | Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies | not yet recruiting | N/A | 20 | Xijing HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT05241249 | Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic Adenocarcinoma | recruiting | Phase 2 | 37 | Susan E. BatesOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06277531 | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)(ECCBILE) | recruiting | — | 99 | Peking University Third HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT03073785 | Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer | active not recruiting | Phase 2 | 46 | University of NebraskaOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04941287 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | May 23, 2025 | clinicaltrials |
| NCT06538857 | CEB-01 in Locally Resectable Pancreatic Cancer | recruiting | Phase 2 | 39 | CEBIOTEXINDUSTRY | 1 | May 23, 2025 | clinicaltrials |
| NCT06986486 | Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma(pCOLA) | recruiting | — | 8 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06967662 | Selective Plasma Adsorption of Extracellular DNA in Prevention of Intraoperative Metastasis in Pancreatic Cancer (Pilot Study)(INTRACOR_pilot) | enrolling by invitation | N/A | 28 | Ilyinskaya Hospital, JSCOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT06406816 | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection | recruiting | Early Phase 1 | 10 | Yongyi ZengOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06515587 | Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer | recruiting | N/A | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06332274 | tislelizUMaB in canceR Patients With molEcuLar residuaL Disease(UMBRELLA) | recruiting | Phase 3 | 717 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT06963060 | Gem+Nab-P+LEN+TIS for Advanced Unresectable BTC (GALENT-BT)(GALENT-BT) | enrolling by invitation | Phase 2 | 44 | Wei GongOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | recruiting | Phase 2 | 51 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04037007 | Efficacy of Fistulotomy for Biliary Cannulation | recruiting | N/A | 320 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | May 1, 2025 | clinicaltrials |
| NCT06946849 | Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment：an Open-label, Randomized, Controlled Phase II Clinical Study(SED-RO-ICC) | not yet recruiting | Phase 2 | 76 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06583993 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients | recruiting | Early Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT05518643 | Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes | recruiting | — | 120 | University of ThessalyOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04634058 | PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed After Standard Treatment | active not recruiting | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05915351 | Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC) | active not recruiting | Phase 2 | 28 | University of Kansas Medical CenterOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 28, 2025source: clinicaltrials